Mesa Laboratories

Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Instruments, Continuous Monitoring, and Biopharmaceutical Development. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators. The Instrument segment designs, manufactures, and markets control instruments and disposable products used in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. The Biopharmaceutical Development segment develops and sells automated systems for protein analysis and peptide synthesis solutions. The Continuous Monitoring segment includes development of systems used to monitor various environmental parameters. The company was founded by Luke R. Schmieder on March 26, 1982 and is headquartered in Lakewood, CO.

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lakewood, Colo., April 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced the closing of its Amended and Restated Credit Agreement (the “Credit Agreement”), which provides up to $200 million of senior secured debt through a syndicate of banks led by JPMORGAN CHASE BANK, N.A. The Credit Agreement includes a $75 million senior secured term loan facility (the “Term Loan”) and a $125 million senior secured revolving credit facility (the “Revolver”), both of which mature in April 2029. The Credit Agreement includes a ten-year amortization schedule and no springing maturity relating to the Company's 1.375% Convertible Senior Notes due August 2025 (the “2025 Notes”). Both the Term Loan and the Revolver bear interest at a rate of SOFR plus an applicable margin ranging from 1.5% to 3.5%, depending on the Company's total Net Leverage Ratio. Proceeds from the Term Loan and Revolver will be used to pay down the Company's 2025 Notes and for normal operating expenditures. The Credit Agreement also allows funds to be used for permitted acquisitions.

MESA LABS ANNOUNCES AMENDMENT TO CREDIT FACILITY AND REPURCHASE OF SENIOR CONVERTIBLE NOTES

SM Energy

SM and MLAB made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 8, 2023.

Best Value Stocks to Buy for April 8th

LAKEWOOD, Colo., April 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 14, 2024, to shareholders of record at the close of business on May 31, 2024.

MESA LABS DECLARES QUARTERLY DIVIDEND

LAKEWOOD, Colo., April 01, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ending March 31, 2024 at approximately 8:00 A.M. Eastern time on Friday, May 24, 2024.

Mesa Laboratories, Inc. to Announce Unaudited Fourth Quarter and Full Fiscal Year 2024 Results on May 24, 2024

LAKEWOOD, Colo, March 15, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB, “Mesa” “we” “our” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced the release of its second annual Environmental, Social and Governance ("ESG") Program Brochure. Rooted in Mesa's unwavering commitment to Protecting the Vulnerable®, this brochure highlights the Company's continued strides in environmental stewardship, social responsibility, and corporate governance.

Mesa Labs Releases Second Annual Responsible Business Program Brochure

Mesa Labs (MLAB) came out with quarterly earnings of $2.02 per share, missing the Zacks Consensus Estimate of $2.04 per share. This compares to earnings of $2.35 per share a year ago.

Mesa Labs (MLAB) Lags Q3 Earnings and Revenue Estimates

LAKEWOOD, Colo., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter (“3Q24”) ended December 31, 2023.

Mesa Labs Announces Third Quarter Results

LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the appointment of Mark Capone to its Board of Directors (the “Board”), effective January 5, 2024.

Mesa Laboratories Appoints Mark Capone to its Board of Directors

LAKEWOOD, Colo., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us” or “our”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, announced the completed acquisition of GKE-GmbH's sterilization indicators business and its accredited, independent testing lab SAL GmbH on October 16th, 2023.   Today, Mesa announced the completion of the acquisition of GKE's Chinese sales entity, Beijing GKE Science & Technology Co. LTD (“GKE China”) effective December 31, 2023, which completes all related transactions. Together, the entities are referred to as “GKE.”

Mesa Labs Completes the Acquisition of GKE Science & Technology Co.

LAKEWOOD, Colo., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2024 at approximately 8:00 A.M. Eastern time on Monday, February 5, 2024.

Mesa Laboratories, Inc. to Announce Second Quarter Results on February 5, 2024

LAKEWOOD, Colo., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced results for its second fiscal quarter (“2Q24”) ended September 30, 2023.

Mesa Labs Announces Second Quarter Results

Lakewood, Colo., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us” or “our”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the completed acquisition of GKE-GmbH's sterilization indicators business and its accredited, independent testing lab SAL GmbH. Additionally, Mesa has entered into a definitive agreement to purchase GKE's Chinese sales entity, Beijing GKE Science & Technology Co. LTD (“GKE China”). The total purchase price for the acquisition of the three entities is €85M (of which €5M is associated with GKE China), which is subject to customary purchase price adjustments and holdbacks. Collectively these three entities are referred to as “GKE”.   The all-cash transactions were or will be funded with proceeds from our credit facility and cash on hand. The GKE China transaction is expected to be completed during our third quarter ending December 31, 2023, and is subject to customary conditions, including receipt of applicable Chinese regulatory approvals.

Mesa Labs Acquires GKE-GmbH Complementary Sterilization Indicators and Healthcare Channels to Mesa's SDC Platform

Mesa Labs ( MLAB ) is a small-cap medical provider of quality control monitoring and validation instruments serving niche markets in healthcare, industrial, pharmaceutical, medical and food processing applications. I have followed this small company for several years and traded the stock for profits in my Healthcare Innovators portfolio.

Bear of the Day: Mesa Labs (MLAB)

LAKEWOOD, Colo., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the second quarter of fiscal year 2024 at approximately 8:00 A.M. Eastern time on Monday, November 6, 2023.

Mesa Laboratories, Inc. to Announce Second Quarter Results on November 6, 2023

LAKEWOOD, Colo., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories Inc (Nasdaq: MLAB; “Mesa” or the “Company”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced its commitment to calculate and disclose scope 1 and 2 greenhouse gas emissions prior to the August 2024 Annual Meeting of Shareholders as part of its sustainability roadmap. This commitment emphasizes Mesa's longstanding commitment to corporate responsibility, including environmental initiatives.

Mesa Laboratories, Inc. Announces Commitment to Disclose Scope 1 and 2 Greenhouse Gas Emissions

Mesa Labs (MLAB) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.67 per share. This compares to earnings of $1.17 per share a year ago.

Mesa Labs (MLAB) Surpasses Q1 Earnings Estimates

LAKEWOOD, Colo., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced results for its first fiscal quarter (“1Q24”) ended June 30, 2023.

Mesa Labs Announces First Quarter Results

LAKEWOOD, Colo., June 21, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the first quarter of fiscal year 2024 at approximately 8:00 A.M. Eastern time on Thursday, August 3, 2023.

Mesa Laboratories, Inc. to Announce First Quarter Results on August 3, 2023

Mesa Labs (MLAB) came out with quarterly earnings of $1.94 per share, missing the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $2.22 per share a year ago.

Mesa Labs (MLAB) Q4 Earnings and Revenues Miss Estimates

LAKEWOOD, Colo., May 25, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q23”) and fiscal year (“FY23”) ended March 31, 2023.

Mesa Labs Announces Unaudited Fourth Quarter and Full Fiscal Year 2023 Results

In Q3, Mesa Laboratories reported mixed results throughout the P&L with soft bottom-line fundamentals. FCF growth still lumpy with contraction in divisional growth.

Mesa Laboratories: Divisional Growth, Valuations Supportive Of Hold

Mesa Labs (MLAB) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is Mesa Labs (MLAB) a Solid Growth Stock? 3 Reasons to Think "Yes"

Mesa Labs (MLAB) delivered earnings and revenue surprises of 11.90% and 5.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Tops Q3 Earnings Estimates

Continued strength in Mesa Laboratories' (MLAB) Clinical Genomics segment is expected to have driven up Q3 sales.

What's in the Cards for Mesa Laboratories' (MLAB) Q3 Earnings?

Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.

News for Mesa Laboratories Stock (MLAB)